CSL Receivables 2017-2024 | CSLLY

CSL receivables for the quarter ending December 31, 2024 were $3.021B, a 30.57% increase year-over-year.

  • CSL receivables for 2024 were $3.021B, a 34.57% increase from 2023.
  • CSL receivables for 2023 were $2.245B, a 33.08% increase from 2022.
  • CSL receivables for 2022 were $1.687B, a 6.04% decline from 2021.

CSL Receivables 2017-2024 | CSLLY

  • CSL receivables for 2024 were $3.021B, a 34.57% increase from 2023.
  • CSL receivables for 2023 were $2.245B, a 33.08% increase from 2022.
  • CSL receivables for 2022 were $1.687B, a 6.04% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$249.7B
Amgen (AMGN)$159.6B
Gilead Sciences (GILD)$147.3B
Vertex Pharmaceuticals (VRTX)$101.1B
Bristol Myers Squibb (BMY)$98.2B
GSK (GSK)$81.6B
Regeneron Pharmaceuticals (REGN)$62.6B
Alnylam Pharmaceuticals (ALNY)$60.1B
Argenex SE (ARGX)$40.5B
Insmed (INSM)$27.4B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$21.5B
Biogen (BIIB)$20.4B
Incyte (INCY)$16.8B
Genmab (GNMSF)$15.9B
Illumina (ILMN)$15.5B
Genmab (GMAB)$15.4B
Ascendis Pharma (ASND)$11.8B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.9B
Moderna (MRNA)$10.5B
Swedish Orphan Biovitrum (BIOVF)$10.3B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.3B
Halozyme Therapeutics (HALO)$8.3B
Roivant Sciences (ROIV)$8B
Guardant Health (GH)$7.3B